Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Sep 24, 2013	Evoke Pharma Announces Pricing of Initial Public Offering of 2,100,000 Shares of Common Stock SAN DIEGO, CA, September 24, 2013 – Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the pricing of its initial public offering of 2,100,000 shares of its common stock at a public offering price of $12.00 per	View HTML Evoke Pharma Announces Pricing of Initial Public Offering of 2,100,000 Shares of Common Stock 10.7 KB
Toggle Summary Sep 30, 2013	Evoke Pharma Announces Closing of Initial Public Offering of 2,100,000 Shares of Common Stock SAN DIEGO , Sept. 30, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the closing of its previously announced initial public offering of common stock.	View HTML Evoke Pharma Announces Closing of Initial Public Offering of 2,100,000 Shares of Common Stock 13.9 KB
Toggle Summary Oct 03, 2013	Evoke Pharma Announces Full Exercise of Underwriters' Over-Allotment Option SAN DIEGO , Oct. 3, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an	View HTML Evoke Pharma Announces Full Exercise of Underwriters' Over-Allotment Option 14 KB
Toggle Summary Nov 05, 2013	Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2013 Financial Results SAN DIEGO , Nov. 5, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Third Quarter of 2013 on Wednesday, November 13, 2013 , after	View HTML Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2013 Financial Results 13.5 KB
Toggle Summary Nov 13, 2013	Evoke Pharma Reports Third Quarter 2013 Results SAN DIEGO , Nov. 13, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2013 .	View HTML Evoke Pharma Reports Third Quarter 2013 Results 28.5 KB
Toggle Summary Nov 26, 2013	Evoke Pharma Selects SynteractHCR as Contract Research Organization for Phase 3 Trial of EVK-001 for Gastroparesis SAN DIEGO , Nov. 26, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the selection of SynteractHCR, Inc. to serve as its primary contract research organization ("CRO") for its	View HTML Evoke Pharma Selects SynteractHCR as Contract Research Organization for Phase 3 Trial of EVK-001 for Gastroparesis 17.1 KB
Toggle Summary Dec 02, 2013	Evoke Pharma Strengthens Executive Team With Appointments of Chief Medical Officer and Senior Director of Clinical Operations Experienced Clinical Executives to Drive Phase 3 Trial of EVK-001 for Gastroparesis	View HTML Evoke Pharma Strengthens Executive Team With Appointments of Chief Medical Officer and Senior Director of Clinical Operations 18.3 KB
Toggle Summary Jan 07, 2014	Evoke Pharma to Present at Biotech Showcase(TM) 2014 SAN DIEGO , Jan. 7, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer is scheduled to present at Biotech Showcase™	View HTML Evoke Pharma to Present at Biotech Showcase(TM) 2014 15 KB
Toggle Summary Jan 22, 2014	Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics SAN DIEGO , Jan. 22, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing	View HTML Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics 16 KB
Toggle Summary Mar 04, 2014	Evoke Pharma to Present at 26th Annual ROTH Conference SAN DIEGO , March 4, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer , R.Ph., will be presenting at the 26 th Annual	View HTML Evoke Pharma to Present at 26th Annual ROTH Conference 14.6 KB